Efficacy and Safety of Fecal Microbiota Transplantation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorGuangzhou First People's Hospital

About this trial

In recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated with an abnormal microbiome structure-dysbiosis, which means the imbalance of the microbiome community. Fecal microbiota transplantation (FMT), the infusion of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to alter the intestine microbiota, is recommended to be performed in Clostridium difficile infection(CDI) as the most effective therapy. It also being used experimentally in the treatment of the disease states linked to dysbiosis of the intestinal microbiota. However, the efficacy and safety of FMT to treat the dysbiosis-associated diseases is still in its infancy. To further verify the indications above, more data is required to be collected through studies.

Eligibility criteria

Qualifiers

Irritable Bowel Syndrome

Ulcerative colitis

Crohn's disease

Constipation

Disqualifiers

Current pregnancy or breast-feeding;

Suffering from other severe diseases, including liver or kidney failure, heart failure, MODS, coma, cerebrovascular accident;

Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, endoscopy, colonoscopy and enema;

Any conditions that may render the efficacy of FMT or at the discretion of the investigators.

Trial design

Treatments tested in this trial

  • Fecal Microbiota Transplantation

Treatment groups

300 Participants
are divided into 40 treatment groups

40

Treatment groups

See each treatment group below.